通过全面基因组分析识别非小细胞肺癌可干预突变以纳入临床试验:欧洲晚期肺癌患者常规检测项目(EPROPA)
EPROPA项目为欧洲五国20个中心的555例晚期非小细胞肺癌患者提供免费分子检测,平均周转时间8天,仅30例(6%)组织样本不适合分析。525例可分析样本中检出570个分子改变,包括264个可靶向致癌改变,205例考虑匹配临床试验,30例入组治疗。接受匹配靶向治疗的可靶向突变患者生存结局显著改善。
要点
- EPROPA项目覆盖希腊、斯洛文尼亚、罗马尼亚、阿尔巴尼亚和意大利20个中心,555例晚期NSCLC患者注册。
- 平均周转时间8天,555例中仅30例(6%)组织样本不适合分子分析。
- 525例可分析样本检出570个分子改变,含264个可靶向致癌改变;30例经分子肿瘤委员会讨论后入组欧洲临床试验。
核心结论
- 该数据证实该程序在真实世界实践场景中的可行性和实用性,支持实施基于下一代测序的NSCLC样本分子表征,以减少欧洲检测、药物和临床试验机会的不平等。
研究设计与样本
- EPROPA是由欧洲肺癌女性组织(WALCE)推动的前瞻性项目,2021年1月至2023年12月纳入希腊、斯洛文尼亚、罗马尼亚、阿尔巴尼亚和意大利五国20个中心的555例晚期NSCLC患者。
- 匿名临床病理数据通过EPROPA网络平台共享,组织样本送至参考中心(都灵大学)分子病理单元进行靶向下一代测序全面基因组分析,分子报告经分子肿瘤委员会讨论评估临床试验资格。
主要发现
- 平均周转时间为8天,555例组织中仅30例(6%)不适合分子分析。
- 525例可分析样本中共检出570个分子改变,包括264个可靶向致癌改变和113例共存突变。
- 报告18个具有潜在胚系和遗传性癌症综合征意义的分子改变。
- 205例患者考虑匹配临床试验,经分子肿瘤委员会讨论后30例入组并接受欧洲可用的临床研究治疗。
- 携带可靶向分子改变并接受匹配靶向治疗的患者生存结局显著改善。
临床怎么用
- 原文未据该程序给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients' access to clinical trials in Europe. METHODS: From January 2021 to December 2023, 20 centers located at five different European countries (Greece, Slovenia, Romania, Albania, and Italy) joined EPROPA, with 555 patients with advanced NSCLC registered to the program. Anonymized patients' clinical-pathological data were shared through the EPROPA web platform and tissue samples were collected at the Molecular Pathology Unit of the Reference Center (University of Turin) for molecular analyses. A comprehensive genomic profiling by a targeted next-generation sequencing approach has been performed and molecular reports have been discussed within the molecular tumor board to assess patients' eligibility for clinical trials. RESULTS: The average turnaround time was eight days, with only 30 out of 555 tissue samples (6%) not suitable for molecular analysis. In the 525 analyzed samples, a total of 570 molecular alterations have been identified, including 264 pathogenic targetable oncogenic alterations and 113 cases with co-occurring mutations. A total of 18 molecular alterations with potential germline and hereditary cancer syndrome implications have been reported. The identification of a clinical trial was considered for 205 patients. After molecular tumor board discussion, 30 patients were enrolled and treated in clinical studies available in Europe. Survival outcomes were significantly improved in patients with targetable molecular alterations receiving a matched targeted therapy. CONCLUSION: This data confirmed the feasibility and usefulness of the program in the real-world practice scenario, supporting the implementation of next-generation sequencing-based molecular characterization of NSCLC samples, to reduce the unequal access to tests, drugs, and clinical trials in Europe.
引用
- Passiglia F, Listì A, Bironzo P, et al. Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA). J Thorac Oncol. 2024. PMID: 39694416. doi:10.1016/j.jtho.2024.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。